References
- Aguiar A. J. Dilatometric behaviour of polymorphic forms of chloramphenicol palrnitate. Journal of Pharmaceutical Sciences 1969; 58: 963–967
- Boyes R. N., Scott D. B., Jebson P. J., Godman M. J., Julian D. G. Pharmacokinetics of lidocaine in man. Clinical Pharmacology and Therapeutics 1971; 12: 105–116
- Chhabra R. S., Pohl R. J., Fouts J. R. A comparative study of xenobiotic-metabolizing enzymes in liver and intestine of various animal species. Drug Metabolism and Disposition 1974; 2: 443–447
- Derendorf H., Möllmann H., Voortman G., van DEN Ouweland F. A., van DE Putte L. B. A., Gevers G., Dequeker J., van Vliet-Daskalopoulou E. Pharmacokinetics of rimexolone after intra-articular administration. Journal of Clinical Pharmacology 1990; 30: 476–479
- Doluiso J. T., La Piana J. C., Dittert L. W. Pharmacokinetics of ampicillin trihydrate, sodium ampicillin, and sodium dicloxacillm following intramuscular injection. Journal of Pharmaceutical Sciences 1971; 60: 715–719
- Farthing M. J. G., Vinson G. P., Edwards C. R. W., Dawson A. M. Testosterone metabolism by the rat gastrointestinal tract, in vitro and in vivo. Gut 1982; 23: 226–234
- Garrod L. P. Choice among penicillins and cephalosporins. British Medical Journal 1974; 3: 96–100
- George C. F. Drug metabolism by the gastrointestinal mucosa. Clinical Pharmacokinetics 1981; 6: 259–274
- Gram L. F., Christiansen J. First-pass metabolism of imipramine in man. Clinical Pharmacology and Therapeutics 1975; 17: 555–563
- Komeno T., Hayashi S., Ishihara S., Itani H., Iwakura H., Takeda K. Studies on 2α,3α-epithio-5α-androstan-17β-ol and related compounds. Part I. Syntheses. Annual Report of Shionogi Research Laboratories 1969; 19: 3–19
- Metzler C. M., Elfring G. K., McEwen A. J. A package of computer programs for pharmacokinetic modeling. Biometrics 1974; 30: 562–563
- Myake T., Tanaka A. Studies on 2α,3α-epithio-5α-androstan-17β-ol and related compounds. Part II. Hormonal and anti-hormonal properties of 2α,3α-epithio-5α-androstan-17β-ol. Annual Report of Shionogi Research Laboratories 1969; 19: 20–38
- Miayake T., Hori T., Kato G., Ide M., Uchida N., Yamaguchi K. 2α,3α-Epithio-5α-androstan-17β-yl 1-methoxycyclopentyl ether (10364-S), a new orally active anti-estrogenic steroid. Steroids 1974; 23: 929–937
- Nakamura Y., Otsuka H., Komeno T. Studies on 2α,3α-epithio-5α-androstan-17β-ol and related compounds. Part XIII. Metabolic pathway. Annual Report of Shionogi Reseaech Laboratories 1970; 20: 152–181
- Prescott L. F., Steel R. F., Ferrier W. R. The effects of particle size on the absorption of phenacetin in man. A correlation between plasma concentration of phenacetin and effects on the central nervous system. Clinical Pharmacology and Therapeutics 1970; 11: 496–504
- Schwartz M. A., Buckwalter F. H. Pharmaceutics of penicillin. Journal of Pharmaceutical Sciences 1962; 51: 1119–1128
- Shand D. S., Rangno R. E. The disposition of propranolol. I. Elimination during oral absorption in man. Pharmacology 1972; 7: 159–168
- Shichiri M., Okada A., Karasaki K., Kawamori R., Shigeta Y., Abe H. Increase in plasma immunoreactive insulin following administration of insulin to the gastrointestinal tract of rabbits. Diabetes 1972; 21: 203–208
- Sumi M., Watari N., Umezawa O., Kaneniwa N. Pharmacokinetic study of carbamazepine and its epoxide metabolite in humans. Journal of Pharmacobio-Dynamics 1987; 10: 652–661
- Takeda K., Komeno T., Kawanami J., Ishihara S., Kadokawa H., Tokura H., Itani H. Bile acids and steroids. XXVII. Thiosteroids (12) steroidal 2,3- and 3,4-episulphides and related compounds. Tetrahedron 1965; 21: 329–351